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Abstract
Nitric oxide (NO) has been implicated in pain processing at the spinal level, but the mechanisms
mediating its effects remain unclear. In the present work, we studied the organization of the major
downstream effector of NO, soluble guanylyl cyclase (sGC), in the superficial dorsal horn of rat.
Almost all neurokinin 1 (NK1) receptor-positive neurons in lamina I (a major source of ascending
projections) were strongly immunopositive for sGC. Many local circuit neurons in laminae I-II
also stained for sGC, but less intensely. Numerous fibers, presumably of unmyelinated primary
afferent (C fiber) origin, stained for calcitonin gene-related peptide or isolectin B4, but none of
these was immunopositive for sGC. These data, along with immunoelectron microscopy results,
imply that unmyelinated primary afferent fibers terminating in the superficial dorsal horn lack
sGC. Double labeling showed that neuronal nitric oxide synthase (nNOS) seldom colocalized with
sGC, but nNOS-positive structures were frequently closely apposed to sGC-positive structures,
suggesting that in the superficial dorsal horn NO acts mainly in a paracrine manner. Our data
suggest that the NK1 receptor-positive projection neurons in lamina I are a major target of NO
released in superficial dorsal horn. NO may also influence local circuit neurons, but it does not act
on unmyelinated primary afferent terminals via sGC.
Keywords
cGMP; C fibers; neurokinin 1 receptor; nitric oxide; pain; substantia gelatinosa
Nitric oxide (NO), a freely-diffusible gas, has been implicated in pain processing in the
spinal cord. Its synthetic enzyme, neuronal nitric oxide synthase (nNOS), is expressed at
high levels in superficial dorsal horn (Dun et al., 1992; Valtschanoff et al., 1992; Saito et al.,
1994). Levels of nNOS and NADPH diaphorase (a histochemical marker for NOS) increase
in the dorsal horn in response to injury or inflammation (Maihofner et al., 2000; Wu et al.,
2001; Liang and Clark, 2004). Importantly, intrathecal administration of NOS inhibitors
attenuates the pain response (Malmberg and Yaksh, 1993; Osborne and Coderre, 1999),
while administration of NO donors can induce hyperalgesia (Kitto et al., 1992; Inoue et al.,
1997). It is thus thought that NO may modulate synaptic efficacy in the superficial dorsal
horn, though the exact mechanisms are still unclear (Willis, 2002). This concept has led to
the suggestion that the NO signaling pathway may provide a novel target for therapeutic
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interventions in the management of pain (Luo and Cizkova, 2000; Thomsen and Olesen,
2001).
In the superficial dorsal horn, NOS concentrates in a subset of islet cells lying at the ventral
border of laminae II, which send processes that make plexi in lamina I and IIi (Valtschanoff
et al., 1992). nNOS is a calcium-dependent enzyme; indirect evidence suggests that
glutamate released from primary afferents may allow calcium entry through N-methyl-D-
aspartate channels, leading to release of NO from these cells (Li et al., 1994; Morris et al.,
1994; Aimar et al., 1998; Kawamata and Omote, 1999). Newly-synthesized NO can then
diffuse to act on neighboring targets within the superficial dorsal horn, possibly including
projection neurons, local circuit interneurons and/or primary afferent terminals (Millan,
1999). However, despite numerous in vitro studies (see, for example, Garry et al., 1994; Lin
et al., 1999; Wu et al., 2001), the targets of NO in the superficial dorsal horn in vivo are still
unclear.
The effects of NO are mediated mainly via soluble guanylyl cyclase (sGC), which catalyzes
the formation of the intracellular second messenger cyclic guanosine monophosphate
(cGMP) upon activation by NO (Schmidt et al., 1993; Bellamy and Garthwaite, 2002). The
NO-sGC-cGMP pathway may help to mediate long-term potentiation in the forebrain
(Schuman and Madison, 1994; Garthwaite and Boulton, 1995; Hawkins et al., 1998).
Pharmacological and electrophysiological evidence from the superficial dorsal horn
implicates cGMP (presumably synthesized by sGC) in pain (Morris et al., 1994; Lin et al.,
1997; Kawamata and Omote, 1999). However, while a previous immunohistochemical study
reported sGC surrounding the central canal, little is known about sGC in the dorsal horn
(Maihofner et al., 2000), though this information is crucial for understanding the role of the
NO-cGMP pathway in pain processing.
Functional sGC is a heterodimer comprising one α and one β subunit (Kamisaki et al., 1986;
Gibb et al., 2003). Four subunits (α1, α2, β1 and β2) have been described, but only α1β1 and
α2β1 heterodimers have been found in the CNS (Koesling et al., 2004). In the present work,
we investigated the cellular and subcellular distribution of sGC in the dorsal horn using
immunohistochemistry for the β1 subunit, previously shown to be an effective marker for
sGC enzyme (Ding et al., 2004). We combined immunohistochemistry for sGC with that for
nNOS and for other neuronal markers to determine whether NO's principal target is primary
afferent fibers, local circuit neurons, or ascending projection neurons; and whether it acts
predominantly in an autocrine or paracrine manner.
MATERIALS AND METHODS
Animal and tissue preparation
Care and treatment of animals were strictly in accordance with institutional and NIH
guidelines. Eight adult male Sprague-Dawley rats (Charles River Laboratories, Wilmington,
MA) were anesthetized deeply with sodium pentobarbital (60 mg/kg, i.p.), then perfused
transcardially with saline (0.9% NaCl) followed by fixative. For light microscopy (LM),
fixation was with freshly depolymerized 4% paraformaldehyde (PF) in 0.1 M sodium
phosphate buffer (PB), pH 7.4; for electron microscopy (EM) or GABA immunostaining,
glutaraldehyde (0.1 %) was added into the above fixative. Spinal cords were removed and
postfixed in 4% PF for 2 hours. Tissue blocks containing lumbar segments 4 (L4) and L5
were mounted on a Vibratome. Transverse and parasagittal sections were cut at 50 μm. For
Western blot analysis, spinal cord tissues containing lumbar enlargement was quickly
removed from two deeply-anesthetized rats and frozen in liquid nitrogen. Tissues were
stored at −80°C until further processed.
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The anti-sGCβ1 antibody (#160897; Cayman Chemicals, Ann Arbor, MI) was raised against
amino acids 188−207 of the β1 subunit of sGC. Its specificity has been documented in
previous studies by Western blot analysis and by colocalization with another antibody
against a different part of sGCβ1 in rat brain (Ding et al., 2004; 2005). For detailed
information and controls regarding the primary antibodies used in this study, see Table 1.
Western blot analysis
Lumbar spinal cord was homogenized in ice-cold lysis buffer (50 mM Tris base, 150 mM
NaCl, 0.5% sodium deoxycholate, 1% Nonidet P40, 0.1% SDS, 2 mM EDTA), containing
protease inhibitors (1 mM each of pepstatin, leupeptin, aprotinin, and phenylmethylsulfonyl
fluoride; all from Sigma), then centrifuged at 16,000 g at 4 °C for 20 min. The supernatant
was collected and protein content determined using a BCA kit (Pierce Biotechnology Inc.,
Rockford, IL). Proteins were separated by SDS-PAGE (10%), transferred to PVDF
membranes (BioTrace; Pall Corporation, Ann Arbor, MI), and blocked with 5% fat-free dry
milk (Carnation) in a mixture of 20 mM Tris, 137 mM NaCl, pH 7.6, and 0.1% Tween-20.
Anti-sGCβ1 antibody was added to the blocking solution (see above) at 0.5 μg/ml. Immune
complexes were visualized using an ECL immunodetection kit; bands were visualized with a
Kodak imaging station.
Immunohistochemistry
Sections were chosen for immunohistochemistry with reference to structures revealed on
Nissl-stained sections. For immunoperoxidase, free-floating sections were treated for 30
minutes with 3% H2O2 in phosphate-buffered saline (PBS) to quench endogenous
peroxidase, preincubated in 10% normal donkey serum (NDS) for 30 minutes, and incubated
overnight on a shaker at room temperature with sGCβ1 primary antibody at 0.5 μg/ml.
Sections were then incubated for 3 hours in biotinylated donkey anti-rabbit IgG (6 μg/ml;
Jackson ImmunoResearch Laboratories, Inc., West Grove, PA) and for 1 hour in
ExtrAvidin-peroxidase complex (0.5 μg/ml; Sigma, St. Louis, MO); peroxidase was
visualized histochemically with diaminobenzidine (DAB). Processed sections were mounted
on slides and air dried. Sections were dehydrated with graded alcohol, cleared with xylene,
and coverslipped with DPX mountant (BDH Chemicals, Poole, England). To control for
method specificity, some sections were processed as above, except that primary or
secondary antibodies were omitted. In all such cases, staining was not detected.
For immunofluorescent multiple-labeling of sGC with other antigens, sGCβ1 was first
stained using tyramide signal amplification (TSA, Hunyady et al., 1996; Shindler and Roth,
1996). Briefly, formaldehyde-fixed free-floating sections were treated for 30 minutes with
3% H2O2 in PBS and preincubated in 10% NDS for 30 minutes. Sections were incubated
overnight on a shaker at room temperature with anti-sGCβ1 primary antibody at 0.05μg/ml,
a concentration too low to be detected with conventional fluorophore-conjungated secondary
antibody. Sections were then incubated for 3 hours in biotinylated donkey anti-rabbit IgG (6
μg/ml; Jackson). The immunostaining was then revealed with a TSA kit (Renaissance TSA
direct kit; DuPont NEN, Wilmington, DE) according to the manufacturer's protocol.
Sections were then incubated in the second (and third) primary antibody [anti-neurokinin 1
(NK1) receptor, anti-glial fibrillary acidic protein (GFAP), anti-calcitonin gene-related
peptide (CGRP) or anti-synaptophysin] overnight (see Table1 for details). Immunostaining
was revealed by incubation for 3 hours with fluorophore-conjugated secondary antibodies
(Jackson). For double staining with GABA, we used tissue fixed with a mixture of 4% PF
and 0.1% glutaraldehyde. Sections were incubated with 1% sodium borohydride for 30
minutes prior to all steps described above. For double labeling with Griffonia simplicifolia
isolectin B4 (IB4), after sGC immunostaining, sections were incubated with FITC-
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conjugated IB4 (0.2 μg/ml; L2895; Sigma) for 3 hours. Following histological processing,
sections were mounted on slides, air-dried and coverslipped with Vectashield mounting
medium (Vector Laboratories, Burlingame, CA). We performed negative controls by
omitting either the first or second primary antibodies. In each case the immunostaining
disappeared in the corresponding channel.
For preembedding EM immunohistochemistry, sections were pretreated with 1% sodium
borohydride for 30 minutes to quench free aldehyde groups, and further processed as for
DAB immunoperoxidase staining for LM. Immunoreacted tissue was rinsed in PB, post-
fixed 1 hour in 1% osmium tetroxide, rinsed in PB, rinsed in 0.1 M maleate buffer (MB, pH
6), stained en bloc 1 hour in 1% uranyl acetate in MB, rinsed, then dehydrated in a graded
ethanol series followed by propylene oxide, infiltrated with a mixture of Epon and Spurr
resins, embedded between two sheets of ACLAR plastic supported by glass slides, and
polymerized at 60°C for 36−48 hours. Thin sections mounted on copper grids were
counterstained with 5% uranyl acetate and Sato's lead and examined on a Philips Tecnai 12
EM (FEI, Hillsboro, OR).
Image acquisition and processing
Immunoperoxidase-reacted sections were examined with a Leitz DMR microscope (Wetzlar,
Germany) under brightfield illumination. Images were acquired with a 12-bit cooled,
charge-coupled device camera (Retiga EX, QImaging, Burnaby, BC, Canada) coupled to a
Macintosh computer. Openlab software (Improvision Inc, Lexington, MA) was used for
image acquisition. Multiple-labeled immunofluorescent images were collected using a Leica
TCS SP2 laser scanning confocal microscope (Wetzlar, Germany). Adobe Photoshop
(version 8.0; Adobe Systems Inc., San Jose, CA) was used to examine the spatial
relationship of the sGCβ1-and nNOS- immunostained puncta by switching between
channels. Adobe Photoshop and Corel Draw (version 12; Corel, Ontario, Canada) were used
to sharpen images, adjust brightness and contrast, and compose final plates.
RESULTS
Detection of sGCβ1 protein in lumbar spinal cord
We used Western blot analysis to verify the presence of sGCβ in spinal cord. The anti-
sGCβ1 antibody detected a single strong band in blots from homogenates of lumbar cord,
migrating at ∼70 kDa, corresponding to the predicted size of the β1 subunit of sGC (Fig. 1).
These data also confirmed that this antibody is specific in spinal cord tissue.
Immunoperoxidase staining of sGCβ1 in superficial dorsal horn
We performed immunohistochemistry for sGCβ1 on sections of L4 and L5 spinal cord (Fig.
2). sGC immunostaining was widely distributed throughout the gray matter of the superficial
dorsal horn. The staining pattern showed a laminar organization: Somatic staining was
strongest in lamina I, moderate in lamina IIo, and weak in IIi; likewise, neuropil staining
was strong in lamina I, and moderate in lamina II (Fig. 2A). Somatodendritic staining was
well-defined in deeper laminae of the dorsal horn. At high magnification, scattered
immunopositive somata could be seen in lamina I (Fig. 2B, C). Numerous large puncta
(arrows in Fig. 2B) and some processes running parallel to the surface of the gray matter
(arrowheads) were densely stained in lamina I. In lamina II, weakly sGCβ1-positive somata
lay among a dense plexus of stained processes (Fig. 2B). On parasagittal sections, most
stained neurons were elongated along the rostro-caudal axis (Fig. 2C). Immunopositive
processes also ran rostro-caudally in laminae I and IIo, but exhibited less orientation in
deeper laminae. To examine the subcellular expression of sGC, we performed
immunoelectron microscopy. Immunoperoxidase reaction product was mainly found in
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somata and dendrites (Fig. 2D, E). A few axon terminals were also immunopositive (Fig.
2F); these terminals did not contain dense core vesicles.
Cellular expression of sGCβ1
The superficial dorsal horn comprises both projection neurons and local interneurons. To
determine whether projection neurons express sGC, we performed double labeling with
NK1 receptor, a marker for the large majority of ascending projection neurons in this region
(Todd et al., 2000). NK1 receptor staining was predominantly in lamina I. Immunostaining
outlined somata and dendrites, in a pattern suggesting selective staining of the plasma
membrane. Nearly all NK1 receptor-positive cells in lamina I was strongly positive for
sGCβ1, as were many NK1 receptor-stained processes (Fig. 3).
To determine whether inhibitory interneurons express sGCβ1, we also performed double
labeling with GABA (Fig. 4). GABA-positive soma were scattered throughout superficial
dorsal horn; most of them also stained for sGC (asterisks, Fig. 4B). Since virtually all
glycinergic interneurons in this region also contain GABA (Todd and Sullivan, 1990), this
result suggests that sGC is expressed in most inhibitory interneurons. However, some sGC-
positive neurons in lamina II were negative for GABA (arrows, Fig. 4C). Considering their
laminar localization, it seems likely that these sGC-positive/GABA-negative neurons are
excitatory interneurons. Notwithstanding previous studies suggesting that sGC may be
present in astrocytes in brain (Nakane et al., 1983;Bellamy et al., 2000), we were unable to
confirm this in spinal cord, using double-labeling with GFAP (data not shown).
Lack of sGCβ1 in C fibers
NO may modulate pain processing by acting on nociceptive primary afferent fibers to
modify transmitter release (Garry et al., 1994; Aimar et al., 1998). We therefore examined
whether sGCβ1 is present in these fibers, by performing double labeling
immunofluorescence with CGRP or IB4, two markers widely used to label peptidergic and
non-peptidergic unmyelinated primary afferents, respectively. CGRP staining was mainly in
laminae I and IIo, whereas IB4 staining was mainly in lamina IIi, as previously reported
(Belyantseva and Lewin, 1999). sGC only rarely colocalized with either CGRP (Fig. 5A, B)
or IB4 (Fig. 5C, D), leading us to conclude that unmyelinated primary afferent fibers contain
little or no sGC.
We further examined this issue at the EM level. A small fraction of axon terminals were
immunopositive for sGCβ1 (Fig. 2F), but the morphology of these terminals was not typical
of primary afferents terminating in this region (Bernardi et al., 1995). Morphologically-
identifiable primary afferent terminals were always immunonegative for sGCβ1. These
include non-glomerular terminals that contain numerous dense core vesicles (Fig. 5E, F) and
the central terminals of both type I and type II glomeruli (Fig. 5G, H). Thus, the EM data are
consistent with our conclusion from immunofluorescence that primary afferent fibers lack
sGC.
The relationship of sGC and nNOS
To investigate the spatial relationship between sources and targets of NO in superficial
dorsal horn, we performed immunofluorescent double-labeling for sGCβ1 and nNOS (Fig.
6). The overall pattern of nNOS staining was consistent with previous reports (Valtschanoff
et al., 1992;Saito et al., 1994). NOS-positive neurons were scattered in superficial dorsal
horn, concentrating in deep lamina IIi (Fig. 6A). NOS-stained processes and puncta formed
a dense plexus in lamina IIi, and a moderately dense plexus in lamina I, whereas staining in
lamina IIo was sparse.
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nNOS and sGC were generally expressed in different cells, though occasional double-
labeled cells were seen (arrow, Fig. 6A). At high magnification, nNOS-positive processes
and puncta throughout the superficial dorsal horn often lay very close to sGC-positive
structures, or made contact with them (Fig. 6B-D). Colocalization of the two antigens in the
same subcellular structures was occasionally detected (arrowhead in C), but apposition was
much commoner. Analysis of 178 nNOS-positive puncta showed that 114 (64%) contacted
sGC-positive puncta, whereas 26 (15%) overlapped or completely colocalized with sGC-
positive puncta; only 38 (21%) failed to exhibit a clear relationship with sGC-positive
profiles. To determine whether contacts between NOS-positive and sGC-positive puncta are
synaptic, we performed triple labeling with synaptophysin, finding that synaptophysin
colocalized with either nNOS or sGC puncta in ∼1/3 of cases (94 of 294 NOS/sGC
contacts). Of these synaptic contacts, ∼70% of the synaptophysin-positive puncta contained
nNOS (66 of 94), and the remainder contained sGC. Thus, much of the influence of NO on
sGC in this region may involve nonsynaptic dendrodendritic interactions (Fig. 6E).
DISCUSSION
sGCβ1 in the spinal cord
Message for sGC subunits has been reported in the spinal cord: α1 and β1 mRNAs were
detected in human spinal cord (Budworth et al., 1999); both α1 and α2 mRNAs were
detected in mouse spinal cord (Liang and Clark, 2004); and α1, α2 and β1 (but not β2)
mRNAs were detected in rat spinal cord (Okamoto, 2004). sGC enzymatic activity has also
been demonstrated in superficial dorsal horn, using cGMP immunostaining after incubation
of the sections with NO donors (Morris et al., 1994; Vles et al., 2000). However, a previous
study found α1 protein in rat spinal cord, but not β1 (Tao and Johns, 2002), contrary to the
present result. The discrepancy may reflect differences in antibodies used in the two studies.
The previous study performed Western blot analysis using a polyclonal antibody thought to
recognize both α1 and β1 subunits. However, this antibody apparently detects the α1 subunit
preferentially, since in lung, which contains similar levels of the two subunits (Kamisaki et
al., 1986), the band corresponding to β1 subunit was much weaker than the α1 band (see Fig.
1A in Tao and Johns, 2002). In contrast, the antibody used in the present study is β1-
specific, detecting a single band corresponding to the β1 subunit throughout the rat brain
(whole brain, Ding et al., 2004; cortex, hippocampus, cerebellum, unpublished data). It
seems unlikely that β2 is the main β subunit in superficial dorsal horn, since β2 mRNA was
not detected in spinal cord (Okamoto, 2004); moreover, we are not aware of published
evidence for β2 protein expression in mammalian tissue (Koesling et al., 2004). Our data
show that β1 is expressed at substantial levels in spinal cord. Enzymatically-active sGC is a
heterodimer (Zabel et al., 1999); since we previously demonstrated massive colocalization
of α and β subunits (Ding et al., 2004), the present immunohistochemical data are likely to
detect the sites of functional enzyme.
sGC and spinal neurons
Combining our data with previous information, we summarize the NO-cGMP pathway in
the superficial dorsal horn in Fig. 7. sGC was expressed at high levels in nearly all NK1
receptor-expressing cells in lamina I, representing the large majority of projection neurons in
this lamina (Todd et al., 2000). nNOS staining forms a dense plexus in lamina I; thus, NO is
well-positioned to influence those projection neurons directly via cGMP. These NK1
receptor-positive projection neurons, which may be the most functionally-significant target
of NO, receive massive synaptic input from peptidergic C fibers that release substance P
(SP) to activate NK1 receptor (Todd, 2002). That these neurons play a pivotal role in pain
processing is supported by experiments showing that their selective ablation markedly
attenuates response to noxious stimuli (Mantyh et al., 1997). We also found weakly sGC-
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positive local circuit neurons, mostly in lamina II. Since both excitatory and inhibitory
interneurons are potential targets of NO, its net effect may be complex, perhaps explaining
the variable effects of NO found in different experimental pain models (see review by Luo
and Cizkova, 2000). Colocalization of sGC and nNOS was infrequent, suggesting that NO
acts in a paracrine manner, though it is not clear from our data whether these interactions are
predominantly at synapses.
sGC and nociceptive primary afferent fibers
We did not detect sGC in unmyelinated primary afferent terminals, at variance with the
conclusions of a previous study (Maihofner et al., 2000). That study provided indirect
evidence that the sGC-positive fibers were of primary afferent origin, whereas we provide
direct evidence, using both double-labeling immunofluorescence and electron microscopy,
that primary afferents lack sGC. However, we cannot exclude that the discrepancy reflects a
species difference between rats and mice, especially since the expression patterns of sGC
may differ between rat and mouse hippocampus (van Staveren et al., 2004). It also remains
possible that C fibers contain sGC at extremely low levels, or in a form our antibody does
not detect.
It has been suggested that NO acts retrogradely on primary afferent terminals to increase
release of neuropeptides, thus explaining its role in chronic pain (Aimar et al., 1998).
However, a study showing that neither NO nor cGMP altered neuropeptide release from
cultured sensory neurons (Dymshitz and Vasko, 1994) calls this hypothesis into question.
The NO donor sodium nitroprusside can evoke the release of SP and CGRP from spinal cord
slices (Garry et al., 1994), but it was not shown that primary afferents are direct targets of
NO. Our data suggest instead that this effect arises indirectly, via actions on local circuit
neurons (though we cannot exclude an effect of NO on primary afferent fibers via a pathway
independent of cGMP).
Besides C fibers, nociceptive stimuli are also conducted by some thinly myelinated Aδ
fibers, which mediate the rapid first phase of pain (Kajander and Bennett, 1992; Millan,
1999). The lack of sGC in type II glomerular terminals, thought to arise from Aδ fibers
(Coimbra et al., 1984; Bernardi et al., 1995), suggests that also Aδ fibers are not direct
retrograde targets of NO. However, a previous study suggests that Aδ fibers provide direct
synaptic input to nNOS-expressing neurons in superficial dorsal horn (Bernardi et al., 1995).
In combination with previous data (Kajander and Bennett, 1992), our results lead to the
hypothesis that NO produced in response to abnormal activity in Aδ fibers at the onset of
pain may sensitize the NK1 receptor-expressing projection neurons, leading to pathological
pain.
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Western blot analysis of sGCβ1 subunit in rat lumbar spinal cord. The anti-sGCβ1 antibody
detected a single band at ∼70 kDa, corresponding to β1 subunit.
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sGCβ1 immunoperoxidase staining in rat superficial dorsal horn at LM (A-C) and EM (D-F).
A, low magnification photomicrograph of immunostaining on transverse section. Staining is
seen throughout the superficial dorsal horn, strong in lamina I and weaker in lamina II. B,
higher magnification view of the boxed region in A. Somatic staining is strong in lamina I.
Numerous large puncta (arrows) and some processes (arrowheads) stain densely in lamina I.
In lamina II, weakly sGC-positive somata lie among a dense plexus of stained processes. C,
parasagittal sections; stained neurons in lamina I were elongated along the rostro-caudal
axis. Immunopositive processes also run rostro-caudally in laminae I and IIo, but more
randomly in deeper laminae. D, a positive soma in lamina I (arrowheads pointing to DAB
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deposits scattered in cytoplasm). A few positive dendrites are also visible (arrows). E,
transverse section of a positive dendrite located in lamina I. F, a stained axonal terminal
makes synaptic contact onto a dendrite in lamina IIi. Scale bars = 100 μm (A); 20 μm (B, C);
2 μm (D); 0.5 μm (E, F).
Ding and Weinberg Page 13














Double labeling of sGCβ1 with NK1 receptor. Boxed area in A is enlarged in B-D. NK1
receptor-positive somata and dendrites are mainly in lamina I. All NK1 receptor-positive
cell bodies contain sGCβ1 staining (arrows). Many of the NK1 receptor-stained processes
also stain for sGC (arrowheads). Scale bars = 50 μm (A); 10 μm (B-D).
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Double labeling of sGCβ1 (green) with GABA (red) in transverse section. A, GABA-stained
cell bodies scattered in superficial dorsal horn; the large majority are also stained for sGC.
High magnification view of boxed areas in A are shown in B and C. B, three GABA-
positive neurons are also immunopositive for sGC (asterisks). C, two sGC-positive cells in
lamina II do not express GABA (arrows). Scale bars = 50 μm (A); 10 μm (B and C).
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The relationship of sGC with primary afferent fibers. A-D: Double labeling of sGCβ1
(green) with two markers for unmyelinated primary afferent fibers, CGRP and IB4 (red) on
transverse (A and C) and parasagittal (B and D) sections. Insets are high magnification view
of the boxed areas. A and B, CGRP-stained primary afferents terminate mainly in lamina I
and IIo. No colocalization of sGC with CGRP was found in transverse or parasagittal
sections. C and D, IB4-stained (non-peptidergic) primary afferents terminate mainly in
lamina IIi. sGC and IB4 staining are in general unrelated both in transverse and parasagittal
section. Occasional contacts are visible (arrowheads), but no clear colocalization. E-H:
sGCβ1 immunoperoxidase staining at EM level showing lack of sGC in primary afferent
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terminals. E, two immunonegative non-glomerular terminals in lamina I that contain dense-
core vesicles (arrowheads) close to an immunopositive dendrite. F, an immunonegative
terminal (likely to be peptidergic for its content of dense-core vesicles, arrowheads) makes
synaptic contact onto an immunopositive dendrite. G, an immunonegative central terminal
of type I (C1) synaptic glomerulus in lamina II. H, a negative central terminal of type II (C2)
synaptic glomerulus in lamina II. Scale bars = 50 μm (A-D); 5 μm (insets of A-D); 0.5 μm
(E-H).
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The spatial relationship of sGCβ1 and nNOS. nNOS-positive cell bodies are scattered in
superficial dorsal horn, most numerous at the ventral border of lamina II. One nNOS-
positive cell body is also stained for sGCβ1 (arrow in A). nNOS-positive processes form a
dense plexus in lamina IIi, lamina I has moderate nNOS immunoreactivity, and lamina IIo
has little. B-D are enlargements of boxed areas in A showing the relationship between the
two antigens in different laminae. nNOS-positive puncta are commonly closely apposed to
sGC-positive puncta; some of these are circled. Occasional apparent colocalization is also
visible (arrowhead). E: Triple labeling with synaptophysin. A few nNOS/sGC contacts
(circles) are associated with synaptophysin (arrowheads), while most of those contacts are
not. Scale bars = 50 μm (A); 10 μm (B-E).
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Schematic diagram of the NO-cGMP pathway in superficial dorsal horn. nNOS-positive
cells, lying mainly in deep lamina II, produce NO when activated, which diffuses to act on
sGC-expressing structures. Concentration of sGC is indicated by darkness of shading. NK1
receptor-expressing projection neurons (black) contain high levels of sGC, and thus may be
the primary target of NO. Excitatory and inhibitory interneurons are also potential targets of
NO. Unmyelinated primary afferents, which lack sGC, are not affected by NO via the cGMP
pathway.
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Table 1
Primary antibodies used in this study.





Chemicals, Ann Arbor, MI;
#160897) prepared against a
synthetic peptide
representing amino acids
188−207 from the β1
subunit of rat sGC.
Recognizes a single band at ∼70 kDa on
Western blot of rat brain Ding et al., 2004)
and spinal cord (Fig. 1).
Staining with this antibody
colocalized in rat brain with
another antibody against a
different part (amino acids
593−614) of sGCβ1 (Ding et
al., 2005).
NK1 receptor 1: 1,000 Rabbit antibody (Advanced
Targeting Systems, San
Diego, CA; AB-N04)
prepared against a peptide
corresponding to amino
acids 393−407 of the rat
NK1 receptor.
Recognizes a protein band at 80−90 kDa on
Western blots of membranes prepared from
cells transfected with the rat substance P
receptor (Vigna et al., 1994).
Staining in rat spinal cord
was blocked by preabsorbing
the antiserum with the
immunizing peptide (Mantyh
et al., 1995)
GABA 0.1 μg/ml Rabbit antibody (Sigma, St
Louis, MO; A2052) raised
against a GABA-BSA
conjugate.
Reacts with GABA and GABA-KLH, but not
with BSA in dot blot immunoassay
manufacturer's product information).
Preabsorption of the
antiserum with free GABA
blocked immunostaining in
rat dorsal horn (Bernardi et
al., 1995)
GFAP 1: 1,000 Mouse monoclonal antibody
(Sigma; clone G-A-5)
prepared against purified
GFAP from pig spinal cord.
Recognizes a single band of 51 kDa on
Western blots of glioma cell extract (Debus
et al., 1983).
Immunostaining was not
detected in cultured brain
cell from GFAP knockout
mice (Pekny et al., 1998).
CGRP 1: 5,000 Guinea pig antibody
(Peninsula, San Carlos, CA;
T-5027) prepared against
human α-CGRP conjugated
to BSA or thyroglobin.
Specificity was verified with
radioimmunoassay by the manufacturer.
The staining pattern of this
antibody in rat dorsal horn is
identical to previous
descriptions (Chung et al.,
1988).
Synaptophysin 1: 1,000 Mouse monoclonal antibody
(Sigma; clone SVP-38). A
synaptosome preparation
from rat retina was used as
the immunogen.
Recognizes one band of ∼38 kDa on
immunoblot of synaptosomal fraction from
rat cerebral cortex (Devoto and Barnstable,
1987).
Immunostaining was not
detected in brain tissue from
synaptophysin-deficient mice
(Eshkind and Leube, 1995)
nNOS 0.25 μg/ml Rabbit antibody (Zymed,
South San Francisco, CA;
61−7000) prepared against
a recombinant protein
consisting of 195 amino
acids from the N-terminal of
rat nNOS protein.
Recognizes a band at ∼150 kDa on Western
blot of rat brain tissue (Burette et al., 2002).
Immunostaining was not
detected in brain tissue from
nNOS knockout mice
(Burette et al., 2002).
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